Table 2.
Multivariate analysis of risk factors of chemo-resistance among endometriosis related ovarian cancer patients
| B | S.E. | P | OR(95%CI) | |
|---|---|---|---|---|
| Age | .337 | .395 | .393 | 1.4(0.65~ 3.04) |
| Bloating | −.057 | .401 | .886 | 0.94(0.43~ 2.07) |
| Emaciation | 1.447 | .791 | .067 | 4.25(0.9~ 20.02) |
| Ca125 in normal range | .728 | .797 | .361 | 2.07(0.43~ 9.87) |
| EM | −.016 | .573 | .978 | 0.98(0.32~ 3.03) |
| FIGO stagea | 1.422 | .497 | .004* | 4.15(1.57~ 10.97) |
| LN metastasis | .980 | .477 | .040* | 2.66(1.05~ 6.78) |
| LN dissection | 1.059 | .440 | .016* | 2.88(1.22~ 6.82) |
| Residual disease | .396 | .405 | .328* | 1.49(0.67~ 3.29) |
| Breast cancer | 1.851 | .918 | .044* | 6.37(1.05~ 38.49) |
| Constant | −5.388 | 1.018 | .000 |
*The difference reached statistical significance. P values were cultivated by Cox regression analysis. The overall test of the above model showed the model was significance, p < 0.0001
aAccording to the classification system of FIGO staging (2013 version)
Abbreviation: Ca125 cancer antigen 125, EM endometriosis, LN lymph node